Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice
Stefano Bartesaghi, Kristina Wallenius, Daniel Hovdal, Mathias Liljeblad, Simonetta Wallin, Niek Dekker, Louise Barlind, Nigel Davies, Frank Seeliger, Maria Sörhede Winzell, Sima Patel, Matt Theisen, Luis Brito, Nils Bergenhem, Shalini Andersson, Xiaorong Peng
Abstract
. This study is the first example of s.c. mRNA therapy showing pre-clinical efficacy in a disease-relevant model, thus, showing the potential for this modality in the treatment of chronic diseases, including T2D and NASH.
Topics & Concepts
FGF21SteatosisSteatohepatitisInsulin resistanceMedicineEndocrinologyInternal medicinePharmacokineticsPharmacodynamicsFatty liverIn vivoSubcutaneous injectionPharmacologyObesityType 2 diabetesInsulinDiabetes mellitusDiseaseBiologyFibroblast growth factorReceptorBiotechnologyFibroblast Growth Factor ResearchKruppel-like factors researchEpigenetics and DNA Methylation